Category: KS

November 2025 BACKGROUND This paper presents the rationale and plan for a cost-effectiveness analysis conducted alongside an open-label, prospective, randomized, two-arm, multicenter, non-inferiority study by the Consortium for Advancing the Prevention and Management of Cancer in People with HIV (AMC) in sub-Saharan Africa. The study compares two commonly used chemotherapy...

November 2024 BACKGROUND AIDS-related Kaposi sarcoma (AIDS-KS) remains a leading cause of morbidity and mortality among people living with HIV in Africa. Mortality among people with AIDS-KS on antiretroviral therapy remains high compared with people on antiretroviral therapy who do not have AIDS-KS. SETTING People living with HIV with Kaposi...

December 2024 Kaposi sarcoma-associated herpes virus (KSHV), also known as human herpes virus 8 (HHV-8), is the primary etiologic cause of Kaposi sarcoma (KS) and KSHV Inflammatory Cytokine Syndrome (KICS). Patients with KICS demonstrate symptoms of systemic inflammation, high KSHV viral load, elevation of inflammatory markers, and increased mortality. Management...

November 2024 Background/Objectives: Kaposi sarcoma (KS) is a common lymphatic endothelial cancer among children with and without HIV in central and eastern Africa. Despite its clinical heterogeneity, its various clinical phenotypes are often grouped together in staging and treatment algorithms. Patients with KS tumor-associated edema, referring to hard, non-pitting lesions...

May 2024 Kaposi sarcoma (KS), caused by human herpes virus 8,1 is the most common cancer in HIV-infected individuals. Immunosuppression is an important risk factor of KS development and before antiretroviral therapy (ART) treatment became widely available in a large proportion of people living with HIV developed KS.2 In 2020,...

February 2024 Epidemic Kaposi sarcoma (KS), also called AIDS-related KS, is one of the most commonly diagnosed cancers in people living with HIV (PLWH). In Malawi, KS is the leading cancer overall, accounting for 34% of all malignancies recorded in the national registry.1 Although the incidence of KS has substantially...

November 2023 BACKGROUND Kaposi sarcoma (KS) is among the most common childhood cancers in Eastern and Central Africa. Pediatric KS has a distinctive clinical presentation compared with adult KS, which includes a tendency for primary lymph node involvement, a considerable proportion of patients lacking cutaneous lesions, and a potential for...

December 2022 INTRODUCTION Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by systemic inflammation, lymphadenopathy, and cytopenias. MCD caused by Kaposi sarcoma herpesvirus (MCD-KSHV) frequently arises in the context of HIV. It can be associated with immune reconstitution inflammatory syndrome (IRIS), but MCD-IRIS is rarely reported in sub-Saharan Africa...

May 2015 – HIV-associated Kaposi Sarcoma is the most common cancer in Malawi. This retrospective cohort study found that providing standard-of-care chemotherapy regimens from the developed world was both effective and feasible.